Methodological survey of designed uneven randomization trials (DU-RANDOM): A protocol

dc.contributor.authorWu, Darong
dc.contributor.authorAkl, Elie A.
dc.contributor.authorGordon, Guyatt H.
dc.contributor.authorDevereaux, Philip James
dc.contributor.authorBrignardello-Petersen, Romina
dc.contributor.authorPrediger, Barbara
dc.contributor.authorPatel, Krupesh
dc.contributor.authorPatel, Namrata
dc.contributor.authorLu, Taoying
dc.contributor.authorZhang, Yuan
dc.contributor.authorFalavigna, Maicon
dc.contributor.authorSantesso, Nancy A.
dc.contributor.authorMustafa, Reem A.
dc.contributor.authorZhou, Qi
dc.contributor.authorBriel, Matthias
dc.contributor.authorSchunëmann, Holger J.
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:42:58Z
dc.date.available2025-01-24T11:42:58Z
dc.date.issued2014
dc.description.abstractBackground: Although even randomization (that is, approximately 1:1 randomization ratio in study arms) provides the greatest statistical power, designed uneven randomization (DUR), (for example, 1:2 or 1:3) is used to increase participation rates. Until now, no convincing data exists addressing the impact of DUR on participation rates in trials. The objective of this study is to evaluate the epidemiology and to explore factors associated with DUR.Methods: We will search for reports of RCTs published within two years in 25 general medical journals with the highest impact factor according to the Journal Citation Report (JCR)-2010. Teams of two reviewers will determine eligibility and extract relevant information from eligible RCTs in duplicate and using standardized forms. We will report the prevalence of DUR trials, the reported reasons for using DUR, and perform a linear regression analysis to estimate the association between the randomization ratio and the associated factors, including participation rate, type of informed consent, clinical area, and so on.Discussion: A clearer understanding of RCTs with DUR and its association with factors in trials, for example, participation rate, can optimize trial design and may have important implications for both researchers and users of the medical literature. © 2014 Wu et al.; licensee BioMed Central Ltd.
dc.identifier.doihttps://doi.org/10.1186/1745-6215-15-33
dc.identifier.eid2-s2.0-84892702435
dc.identifier.pmid24456965
dc.identifier.urihttp://hdl.handle.net/10938/30155
dc.language.isoen
dc.relation.ispartofTrials
dc.sourceScopus
dc.subjectDesigned uneven randomization trials
dc.subjectParticipation rate
dc.subjectTrial participation
dc.subjectHumans
dc.subjectInformed consent
dc.subjectJournal impact factor
dc.subjectLinear models
dc.subjectPatient selection
dc.subjectPeriodicals as topic
dc.subjectRandomized controlled trials as topic
dc.subjectResearch design
dc.subjectSample size
dc.subjectArticle
dc.subjectData analysis
dc.subjectData extraction
dc.subjectDescriptive research
dc.subjectHuman
dc.subjectMedical literature
dc.subjectPublication
dc.subjectRandomized controlled trial (topic)
dc.subjectStudy design
dc.subjectSystematic review
dc.titleMethodological survey of designed uneven randomization trials (DU-RANDOM): A protocol
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2014-5288.pdf
Size:
463.03 KB
Format:
Adobe Portable Document Format